Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.70 |
| ▸ | JAK1 | P23458 | 3/20 | 0.70 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.53 |
| ▸ | AKT2 | P31751 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183418 | 1.00 | JAK3 (0.70) | JAK3JAK1DOT1LAKT2GSK3B | |
| SCHEMBL16764926 | 0.83 | JAK3 (0.73) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL16764960 | 0.83 | JAK3 (0.73) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL20125438 | 0.82 | JAK3 (0.95) | JAK3JAK1AKT2GSK3BKIT | |
| SCHEMBL2024604 | 0.78 | JAK3 (1.00) | JAK3JAK1DOT1LAKT2GSK3B | |
| SCHEMBL20582750 | 0.75 | JAK3 (0.60) | JAK3JAK1DOT1L | |
| SCHEMBL15208812 | 0.75 | JAK3 (0.56) | JAK3JAK1 | |
| SCHEMBL20183413 | 0.75 | ADK (0.62) | JAK3JAK1DOT1L | |
| SCHEMBL20183343 | 0.75 | ADK (0.62) | JAK3JAK1DOT1L | |
| SCHEMBL20183306 | 0.75 | ADK (0.62) | JAK3JAK1DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885DOT1L 1558/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885DOT1L 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.